Literature DB >> 28741837

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

.   

Abstract

OBJECTIVES: The aim of the study was to evaluate differences in immunovirological response to combination antiretroviral therapy (cART) in migrant and native men and women within a European collaboration of HIV cohorts Collaboration of Observational HIV Epidemiological Research in Europ (COHERE) in EuroCoord, 2004-2013.
METHODS: Migrants were defined as those with geographical origin (GO) different from the reporting country and were grouped as originating from Western Europe and Western Countries (WEWC), Eastern Europe (EE), North Africa and the Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), Caribbean (CRB) and Asia/Oceania (ASIA/OCE). Native (NAT) individuals were defined as those originating from the reporting country. CD4 cell counts were modelled using piecewise linear mixed-effects models with two slopes, whereas models to estimate subdistribution hazard ratios (sHRs) were used for time to virological response (VR) (i.e. time from cART initiation to the first of two successive HIV RNA measurements < 400 HIV-1 RNA copies/ml).
RESULTS: Of 32 817 individuals, 25 799 (78.6%) were men. The percentage of migrants was higher in women (48.9%) than in men (21.2%) and migrants from SSA accounted for the largest migrant group (29.9% in men and 63.3% in women). Migrant men and women from SSA started at lower CD4 cell counts than NAT individuals, which remained lower over time. VR was ≥ 85% at 12 months for all groups except CRB women (77.7%). Compared with NAT men and women, lower VR was experienced by NAME [sHR 0.91; 95% confidence interval (CI) 0.86-0.97] and SSA (sHR 0.88; 95% CI 0.82-0.95) men and CRB (sHR 0.77; 85% CI 0.67-0.89) women, respectively.
CONCLUSIONS: Immunovirological response to cART in Western Europe varies by GO and sex of patients. ART benefits are not equal for all, underlining the point that efforts need to prioritize those most in need.
© 2017 British HIV Association.

Entities:  

Keywords:  zzm321990HIVzzm321990; combination antiretroviral therapy; immunovirological response; migrants; sex

Mesh:

Substances:

Year:  2017        PMID: 28741837     DOI: 10.1111/hiv.12536

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  3 in total

1.  Longitudinal virological outcomes and factors associated with virological failure in behaviorally HIV-infected young adults on combination antiretroviral treatment in the Netherlands, 2000 to 2015.

Authors:  Annouschka M Weijsenfeld; Charlotte Blokhuis; Martijn M Stuiver; Ferdinand W N M Wit; Dasja Pajkrt
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

2.  Respective roles of migration and social deprivation for virological non-suppression in HIV-infected adults on antiretroviral therapy in France.

Authors:  Mariem Raho-Moussa; Marguerite Guiguet; Céline Michaud; Patricia Honoré; Christia Palacios; François Boué; Mohammed Azghay; Imad Kansau; Véronique Chambrin; Tania Kandel; Marion Favier; Elsa Miekoutima; Naomi Sayre; Carole Pignon; Michka Shoai; Olivier Bouchaud; Sophie Abgrall
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

3.  Promoting HIV, Hepatitis B Virus, and Hepatitis C Virus Screening Among Migrants With a Language Barrier: Protocol for the Development and Evaluation of an Electronic App (Apidé).

Authors:  Frédérique Thonon; Saleh Fahmi; Olivia Rousset-Torrente; Pascal Bessonneau; James W Griffith; Carter Brown; Olivier Chassany; Martin Duracinsky
Journal:  JMIR Res Protoc       Date:  2021-05-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.